MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF metastatic colorectal cancer

Van Cutsem, 2016, ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Ann Oncol, 27, 1386, 10.1093/annonc/mdw235 Benson, 2021, National Comprehensive Cancer Network. Colon cancer, version 2, 2021, J Natl Compr Canc Netw, 19, 329, 10.6004/jnccn.2021.0012 Johnsson, 2013, A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial, Ann Oncol, 24, 2335, 10.1093/annonc/mdt236 Simkens, 2015, Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group, Lancet, 385, 1843, 10.1016/S0140-6736(14)62004-3 Hegewisch-Becker, 2015, Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial, Lancet Oncol, 16, 1355, 10.1016/S1470-2045(15)00042-X Stein, 2016, Effect of application and intensity of bevacizumab-based maintenance after induction chemotherapy with bevacizumab for metastatic colorectal cancer: a meta-analysis, Clin Colorectal Cancer, 15, e29, 10.1016/j.clcc.2015.12.005 Tamburini, 2016, Maintenance based bevacizumab versus complete stop or continuous therapy after induction therapy in first line treatment of stage IV colorectal cancer: a meta-analysis of randomized clinical trials, Crit Rev Oncol Hematol, 104, 115, 10.1016/j.critrevonc.2016.05.016 Pietrantonio, 2019, Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial, JAMA Oncol, 5, 1268, 10.1001/jamaoncol.2019.1467 West, 2017, Novel precision medicine trial designs: umbrellas and baskets, JAMA Oncol, 3, 423, 10.1001/jamaoncol.2016.5299 Schmoll, 2018, MODUL – a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach, J Cancer Res Clin Oncol, 144, 1197, 10.1007/s00432-018-2632-6 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 Hegde, 2018, Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics, Semin Cancer Biol, 52, 117, 10.1016/j.semcancer.2017.12.002 Wallin, 2016, Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma, Nat Commun, 7, 10.1038/ncomms12624 Saltz, 2008, Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study, J Clin Oncol, 26, 2013, 10.1200/JCO.2007.14.9930 Brookmeyer, 1982, A K-sample median test for censored data, J Am Stat Assoc, 77, 433 Sonbol, 2020, The role of maintenance strategies in metastatic colorectal cancer: a systematic review and network meta-analysis of randomized clinical trials, JAMA Oncol, 6, 10.1001/jamaoncol.2019.4489 Taieb, 2016, Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer, J Natl Cancer Inst, 109, 10.1093/jnci/djw272 Stintzing, 2018, Recent advances in understanding colorectal cancer, F1000Res, 7, F1000, 10.12688/f1000research.14604.1 Cremolini, 2021, FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO, Ann Oncol, 32, S1294, 10.1016/j.annonc.2021.08.2094 Eng, 2019, IMblaze370 Investigators. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open label, phase 3, randomised, controlled trial, Lancet Oncol, 20, 849, 10.1016/S1470-2045(19)30027-0 Gomez-Roca, 2021, LEAP-005: a phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—results from the colorectal cancer cohort, J Clin Oncol, 39